Evalstotug

DB19410InvestigationalProtein Based Therapies

Evalstotug is under investigation in clinical trial NCT05271604 (A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4
Curator reviewed
Also known as: Gamma1 heavy chain (1-447) [VH (Homo sapiens IGHV3-30*02 (91.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 · Immunoglobulin G1 [de-448-lysine], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal BA3071 γ1-chain), disulfide with human monoclonal BA3071 κ-chain, dimer · Immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody
Code names: BA-3071

Resolves to

Compound

UNIIZT62XSC86FCAS2460399-39-5

Targets

P16410CTLA4

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Evalstotug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account